|
Through in-house and collaborative development, we have established a broad pipeline of gene-based medicines. Our in-house capabilities span research, clinical development, regulatory affairs and manufacturing. At the end of 2009, our staff numbered 65, mainly based in our laboratories and offices in Oxford. We also have a wholly owned subsidiary, BioMedica Inc, based in San Diego, USA.
Our two lead programmes are a gene therapy for Parkinson’s disease (ProSavin) in Phase I/II development and a therapeutic cancer vaccine (TroVax) in Phase II development. Through our collaboration with sanofi-aventis, two of the four gene therapies for ocular diseases are expected to enter clinical development in 2010.
In addition to sanofi-aventis, our partners include Pfizer, Sigma-Aldrich and charitable organisations such as the Foundation Fighting Blindness, the ALS Therapy Development Institute and the Motor Neurone Disease Association. Our proprietary LentiVector technology is used extensively in drug discovery and has been licensed by leading pharmaceutical companies, including Biogen Idec, GlaxoSmithKline, Merck & Co and Pfizer for their own research activities.
We maintain the highest standards of integrity in our dealings with all parties, including shareholders, employees, patients, healthcare professionals, partners, and licensees. Through scientific, commercial and operational excellence, we aim to maximise returns for shareholders.
Oxford BioMedica is a member of the UK BioIndustry Association and the US Biotechnology Industry Organization.
|
 |
|
